As clinical momentum grows for novel DDR targets such as ATR, CHK1/2, WEE1, and DNA-PK, this forum delivers a front-row seat ...

Returning as Europe’s longest-standing and definitive ADC forum, the 16th World ADC London is the week for anyone working in ...

Along with Verona, MSD has been adding to its post-Keytruda prospects with a string of acquisitions and licensing deals in ...

In a landscape where access is no longer an after-thought, but a strategic imperative, this summit tackles the full lifecycle ...

Welcome back to Changing Faces, in our final round-up for August and September there are plenty of Board appointments to ...

Electra Therapeutics has garnered the funds it needs to complete a pivotal trial of its lead drug, angling to become the ...

And this is where targeted radiotherapeutics come in. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr ...

ESMO 2025 showcased the breadth and urgency of breast cancer research, which remains one of the most diagnosed malignancies ...

Inizio brings in seasoned pharma exec for top job. A new chapter begins at Inizio with the appointment of Ryan Quigley as CEO ...

Inherited cardiac conditions (ICCs) can lead to heart failure, and fewer than half of all people diagnosed with heart failure ...

When everything comes together, pharma and biotech can do a great deal even if some of the data isn’t as strong, as long as ...

We’ve also seen investors lean into neurodegenerative and CNS conditions like schizophrenia. Karuna’s $14 billion acquisition ...